DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181454

Clinical profiles and trends in CD4+ counts to first-line antiretroviral therapy among HIV/AIDS patients in western part of Odisha state of India

Pradhan B., Majhi C., Murmu B.

Abstract


Background: HIV infection is globally pandemic and about 36.7 million people living with HIV/ AIDS (PLHA) in 2016. At present CD4+ count is the gold standard of immunological marker of disease severity. Highly active antiretroviral therapy (HAART) is the first line of treatment to improve CD4 count. AIMS AND OBJECTIVES of study was to observe the clinical profiles and response in CD4+ counts to first-line HAART in PLHA and their adverse reactions.

Methods: Total 153 PLHA with CD4+ counts <250/µl was consecutively taken in the study and detail clinical examinations, baseline CD4+ counts and body weights were noted. HAART was started in 26 (16.99%), 37 (24.18%), 78 (50.98%) and 12 (7.84%) cases in WHO clinical stages of I, II, III, and V respectively and CD4+ counts, body weight and any adverse drug reactions were noted at 15 days, 3, 6, 18 and 24 months intervals and data were collected and analyzed.

Results: Out of 153 cases 89 were male and 64 were female. Mean age was 35.4±9.08 years for male and 30.2±5.75 years for female. Mean baseline CD4+ count was 202±75/µl and mean body weight was 47.44kg. Mean CD4+ count was increased to 314.22±166.53, 343±194.02, 378±221.30 and 299.6±146.55/µl at 6, 12, 18 and 24 months respectively. Commonest adverse drug reaction was headache and GIT side effects.

Conclusions: HAART improves clinical and immunological parameter CD4+ count in PLHA, irrespective of their clinical stages. Headache and GIT manifestations are commonest adverse drug reactions.


Keywords


Antiretroviral therapy, CD4+ Cell count, HIV

Full Text:

PDF

References


Rewari BB, Joshi PL. Epidemiology of HIV/AIDS with special reference to India. Medicine update. 2003;77-86.

Kilby M, Saag MS. Pathogenesis of HIV-1 infection: In Manual of Therapeutics. 2nd Ed, Editor: Powderly WG. Lippincott Williams and Wilkins, London, 2001.

Dalgleish AG, Beverly PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 antigen is an essential component of the receptor for the AIDS retrovirus.Nature.1985:312(5996):763-7.

Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G, NIH Conference. Immunopathogenesis mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med.1991;114(8);678-93.

Gottieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, ET AL. Equal plasma viral loads predicts a similar rates of CD4+ cell decline in human immunodeficiency virus(HIV) Type-1 and Type-2 infected individuals from Senegal, West Africa. Jour Infect Dis. 2002;185(7):905-145.

Lapri AC, Phillips AN, Monforte AD, Castelli F, Antinori A. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS. 2001;15(8);983-90.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach, 2010. Available at: http://www.who.Int/hiv/pub/arv /adult 2010/en/.

Pallela Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. HIV out patient study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. NEJM. 1998;338(13):853-60.

Fauci AS, Lane HC. HIV Disease: AIDS and Related Disorders In: Harrison’s Principles of Internal Medicine. 19th Ed. Mc. Graw Hill. 2015:215.

Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, et al. CD4 cells count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, North Ethiopia: a retrospective cross-sectional study. Plosone. 2015;10(3):E0122583.

Omati CE, Udezi WA, Edoise RE. Hematological aspect of antiretroviral naïve HIV patients in a Nigerian tertiary hospital: Laboratory and clinical considerations. Int Jour of Biological and chemical science. 2007;1(2):176-80.

Omati CE, Udezi WA, Edoise RE. Hematological aspect of antiretroviral naïve HIV patients in a Nigerian tertiary hospital: Laboratory and clinical considerations. Int Jour Biological and chemical science. 2007;1(2):176-80.

Glynn JR, Caraël M, Auvert B, Kahindo M, Chege J, Musonda R, Kaona F, et al. Study Group on the Heterogeneity of HIV Epidemics in African Cities. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. Aids. 2001;15:S51-60.

Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenol B, Saghayam S, et al. Gender based differences in treatment and outcome among HIV patients in South India. J Women’s Health. 2008;17(9):1471-5.

Kamaya MR, Semital FC, Quinn TC, Ronald A, Nyamameya D et al. Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. African health Science. 2004;4(2):94-101.

Kitahata M, Dillingham P, Van Rompaey S. Initiating potent combination antiretroviral therapy with in 1 year of the first clinic visit for patients at all CD4 cell count level is associated with better long-term outcomes. 2002. Available at: http://www.Medscape.org.view article.

Akinbami A, Oshinaike O, Adeyemo T, Adediran A, Dosunmu O, Dada M, et al. Hematologic Abnormalities in Treatment-naïve HIV patients. Infectious Diseases: Research and Treatment. 2010;3:IDRT-S6033.

Martinez E, Macroft A, Garcin Veijo MA, Pirez-Cuevas JB, Blanco JL, et al. Risk of lipodystrophy in HIV-1 infected patient treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(9256):592-98.

Badri M, Lawn SD, Wood R. Utility of CD4 cell count for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC infectious diseases. 2008;8(1)89.

Highley L. Poor CD4 cell recovery on antiretroviral therapy is linked to late treatment leads to adverse outcome. In: HIV and Hepatitis. Com-Converge of the 17th Conference on retroviruses and opportunistic infections (CTROI 2010). San Francisco, 2010.